Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors

NCT02341625 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT02341625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02341625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Terminated
Start date
June 19, 2015
Completion date
May 7, 2020
Enrollment
126 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer